The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed, and funded by an Alkermes company.
Showing 10 of 103 results
Sort by date:
Ascending
Mar 2023
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
Schizophrenia Bulletin
AUTHOR(S)
Mar 2023
Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study
The Journal of Clinical Psychiatry
AUTHOR(S)
May 2023
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine
CNS Spectrums
AUTHOR(S)
Jul 2023
Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients
CNS Spectrums
AUTHOR(S)
Aug 2023
Clinical, Economic, and Humanistic Outcomes Associated with Obesity Among People with Bipolar I Disorder in the United States: Analysis of National Health and Wellness Survey Data
ClinicoEconomics and Outcomes Research
AUTHOR(S)
Jan 2024
Treatment Journey and Healthcare Resource Use Among Patients With Alcohol Use Disorder Who Initiated Extended-Release Naltrexone: An Analysis of Veterans Affairs Data
Substance Use: Research and Treatment
AUTHOR(S)
Jan 2024
Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis
Innovations in Clinical Neuroscience
AUTHOR(S)
Feb 2024
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia
Journal of Clinical Psychiatry
AUTHOR(S)
Mar 2024
Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial
Sleep Medicine: X
AUTHOR(S)
May 2024
Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial
Sleep Medicine: X
AUTHOR(S)
